Alphanate SD/HT

ApprovedActive

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Von Willebrand Disease

Conditions

Von Willebrand Disease

Trial Timeline

Sep 1, 2007 → Mar 1, 2029

NCT ID

NCT00555555

About Alphanate SD/HT

Alphanate SD/HT is a approved stage product being developed by Grifols for Von Willebrand Disease. The current trial status is active. This product is registered under clinical trial identifier NCT00555555. Target conditions include Von Willebrand Disease.

What happened to similar drugs?

3 of 6 similar drugs in Von Willebrand Disease were approved

Approved (3) Terminated (0) Active (3)

🔄Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing AgentsRochePhase 3

🔄BiostateCSLPhase 3

✅Blood coagulation Factor VIII and vWF, humanCSLApproved

🔄BiostateCSLPhase 3

✅VoncentoCSLApproved

✅plasma-derived FVIII/VWF concentrateGrifolsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00555555	Approved	Active	Sep 1, 2007	Mar 1, 2029	Von Willebrand Disease
NCT00323856	Approved	Completed	Apr 8, 2003	Dec 14, 2018	Severe Hemophilia A

Competing Products

14 competing products in Von Willebrand Disease

See all competitors

Product	Company	Stage	Hype Score
Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate	Roche	Pre-clinical	33
Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents	Roche	Phase 3	47
Neumega (Oprelvekin, Interleukin 11, IL-11)	Pfizer	Phase 2	27
Oprelvekin, Interleukin 11, IL-11	Pfizer	Phase 2	35
recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11	Pfizer	Phase 2	35
efanesoctocog alfa (BIVV001)	Sanofi	Phase 1	29
Biostate	CSL	Phase 3	40
Voncento®	CSL	Pre-clinical	26
Blood coagulation Factor VIII and vWF, human	CSL	Approved	43
Biostate® + Biostate®	CSL	Phase 2/3	38
VWF/FVIII products	CSL	Pre-clinical	26
Biostate	CSL	Phase 3	40
Voncento	CSL	Approved	43
plasma-derived FVIII/VWF concentrate	Grifols	Approved	47